COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry.
Gabriel BstehHamid AssarHarald HegenBettina HeschlFritz LeutmezerFranziska Di PauliChristiane GradlGerhard TraxlerGudrun ZulehnerPaulus RommerPeter WipflerMichael GugerChristian EnzingerThomas Bergernull nullPublished in: PloS one (2021)
In a population-based MS cohort, COVID-19 outcome was not associated with exposure to DMT and immunosuppressive DMT when accounting for other already known risk factors. This provides reassuring evidence that COVID-19 risk can be individually anticipated in MS and-except for a very small proportion of high-risk patients-treatment decisions should be primarily focused on treating MS rather than the pandemic.
Keyphrases
- coronavirus disease
- multiple sclerosis
- sars cov
- risk factors
- mass spectrometry
- end stage renal disease
- ms ms
- respiratory syndrome coronavirus
- chronic kidney disease
- newly diagnosed
- ejection fraction
- prognostic factors
- white matter
- peritoneal dialysis
- type diabetes
- patient reported outcomes
- cardiovascular disease
- coronary artery disease
- patient reported
- combination therapy